Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 4/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | XDH | P47989 | 2/20 | 0.44 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | CA4 | P22748 | 1/20 | 0.44 |
| ▸ | DPP4 | P27487 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL773768 | 0.91 | CYP19A1 (0.47) | CYP19A1TP53CYP3A4XDHCYP1A1 | |
| SCHEMBL8063267 | 0.86 | GSK3B (0.49) | CYP19A1TP53CYP3A4XDHCYP1A1 | |
| SCHEMBL2879031 | 0.86 | ABCG2 (0.53) | CYP19A1CYP3A4HPGDALDH1A1MAPK1 | |
| SCHEMBL28464161 | 0.85 | CYP1A1 (0.53) | CYP19A1TP53CYP3A4XDHCYP1A1 | |
| SCHEMBL15573731 | 0.83 | ABCG2 (0.56) | CYP19A1CYP3A4MAPTHPGDNPC1 | |
| SCHEMBL1508796 | 0.83 | MEN1 (0.49) | CYP19A1CYP3A4CYP1A1CYP1A2CYP1B1 | |
| SCHEMBL3364490 | 0.82 | ABCG2 (0.54) | CYP19A1CYP3A4MAPTHPGDALDH1A1 | |
| SCHEMBL126042 | 0.82 | NR3C1 (0.51) | MAPTHPGDALDH1A1HSD17B10NR3C1 | |
| SCHEMBL5085611 | 0.81 | CYP3A4 (0.49) | CYP19A1TP53CYP3A4XDHCYP1A1 | |
| SCHEMBL10425234 | 0.81 | KDM4E (0.46) | CYP3A4XDHHPGDPKMNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115315195-B | Hydroxy-and methoxy-substituted flavonoids and use thereof | 弗门尼舍有限公司 | 2024-07-02 | — | — | CN | claimed |
| US-20240099344-A1 | HYDROXY- AND METHOXY-SUBSTITUTED FLAVONOIDS AND THEIR USE | FIRMENICH SA (CH) | 2024-03-28 | — | — | US | claimed |
| CN-115315195-A | Hydroxy-and methoxy-substituted flavonoids and their use | 弗门尼舍有限公司 | 2022-11-08 | — | — | CN | claimed |
| CN-119912420-A | Alpinetin derivative and preparation method, pharmaceutical composition and application thereof | 首都医科大学附属北京世纪坛医院 | 2025-05-02 | — | — | CN | disclosed |
| CN-115315195-B | Hydroxy-and methoxy-substituted flavonoids and use thereof | 弗门尼舍有限公司 | 2024-07-02 | — | — | CN | disclosed |
| US-20240099344-A1 | HYDROXY- AND METHOXY-SUBSTITUTED FLAVONOIDS AND THEIR USE | FIRMENICH SA (CH) | 2024-03-28 | — | — | US | disclosed |
| CN-117534644-A | Preparation method of alpinetin | 深圳创元生物医药科技有限公司 | 2024-02-09 | — | — | CN | disclosed |
| EP-4258900-A1 | HYDROXY- AND METHOXY-SUBSTITUTED FLAVONOIDS AND THEIR USE | Firmenich SA (CH) | 2023-10-18 | — | — | EP | disclosed |
| CN-115315195-A | Hydroxy-and methoxy-substituted flavonoids and their use | 弗门尼舍有限公司 | 2022-11-08 | — | — | CN | disclosed |
| WO-2022189156-A1 | HYDROXY- AND METHOXY-SUBSTITUTED FLAVONOIDS AND THEIR USE | FIRMENICH SA (CH) | 2022-09-15 | — | — | WO | disclosed |
| CN-105334174-A | Method for determining content of main active components in Alpinia katsumadai by using ultraviolet spectrophotometry | UNIV HAINAN NORMAL | 2016-02-17 | — | — | CN | disclosed |
| WO-2007115181-A9 | COMPOUNDS EXHIBITING EFFLUX INHIBITOR ACTIVITY AND COMPOSITIONS AND USES THEREOF | EASTMAN CHEM CO (US) | 2008-04-03 | — | — | WO | disclosed |
| US-20070254859-A1 | Compounds exhibiting efflux inhibitor activity and composition and uses thereof | EASTMAN CHEMICAL COMPANY | 2007-11-01 | — | — | US | disclosed |
| WO-2007115181-A2 | COMPOUNDS EXHIBITING EFFLUX INHIBITOR ACTIVITY AND COMPOSITIONS AND USES THEREOF | EASTMAN CHEMICAL COMPANY (US) | 2007-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254859-A1 | Compounds exhibiting efflux inhibitor activity and composition and uses thereof | ABCC4, NCOA4, NR4A3 | CYP19A1 214/4885TP53 3361/4885CYP3A4 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.